Concepts (241)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| T-Lymphocytes, Regulatory | 26 | 2020 | 57 | 6.070 |
Why?
|
| Forkhead Transcription Factors | 15 | 2020 | 74 | 3.310 |
Why?
|
| DNA-Binding Proteins | 12 | 2021 | 522 | 2.660 |
Why?
|
| Transcription Factors | 9 | 2021 | 653 | 2.250 |
Why?
|
| CD4-Positive T-Lymphocytes | 10 | 2019 | 251 | 1.470 |
Why?
|
| Ikaros Transcription Factor | 4 | 2019 | 8 | 1.350 |
Why?
|
| Receptors, Interleukin-2 | 10 | 2007 | 29 | 1.320 |
Why?
|
| Cell Differentiation | 12 | 2021 | 562 | 1.230 |
Why?
|
| Autoimmune Diseases | 5 | 2015 | 55 | 1.050 |
Why?
|
| T-Lymphocyte Subsets | 5 | 2014 | 84 | 1.040 |
Why?
|
| Lymphocyte Activation | 13 | 2019 | 222 | 0.970 |
Why?
|
| Antigens, Differentiation | 2 | 2019 | 24 | 0.790 |
Why?
|
| Mice | 33 | 2021 | 5668 | 0.760 |
Why?
|
| Interleukin-2 | 6 | 2015 | 87 | 0.730 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2019 | 57 | 0.730 |
Why?
|
| Mice, Inbred C57BL | 17 | 2021 | 1530 | 0.710 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 92 | 0.680 |
Why?
|
| Immune Tolerance | 7 | 2014 | 61 | 0.650 |
Why?
|
| Animals | 37 | 2021 | 14307 | 0.640 |
Why?
|
| Autoimmunity | 6 | 2019 | 52 | 0.580 |
Why?
|
| Mice, Knockout | 15 | 2021 | 897 | 0.580 |
Why?
|
| T-Lymphocytes | 4 | 2021 | 341 | 0.500 |
Why?
|
| Mice, Transgenic | 9 | 2021 | 608 | 0.450 |
Why?
|
| Calcium | 3 | 2011 | 445 | 0.450 |
Why?
|
| Muscle, Skeletal | 2 | 2011 | 257 | 0.420 |
Why?
|
| Muscle Contraction | 1 | 2011 | 63 | 0.400 |
Why?
|
| Inflammatory Bowel Diseases | 4 | 2019 | 85 | 0.390 |
Why?
|
| Cell Proliferation | 6 | 2019 | 1149 | 0.390 |
Why?
|
| Thymus Gland | 2 | 2011 | 77 | 0.380 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 6 | 2015 | 18 | 0.370 |
Why?
|
| Aging | 2 | 2011 | 639 | 0.350 |
Why?
|
| Phenotype | 4 | 2020 | 650 | 0.340 |
Why?
|
| Signal Transduction | 6 | 2015 | 1802 | 0.330 |
Why?
|
| Coculture Techniques | 5 | 2011 | 96 | 0.320 |
Why?
|
| Calcium Signaling | 4 | 2011 | 95 | 0.320 |
Why?
|
| Gastritis | 1 | 2006 | 11 | 0.290 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2006 | 19 | 0.290 |
Why?
|
| B-Lymphocytes | 2 | 2006 | 181 | 0.290 |
Why?
|
| Mice, Inbred BALB C | 8 | 2010 | 649 | 0.260 |
Why?
|
| Nerve Tissue Proteins | 2 | 2019 | 338 | 0.260 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2019 | 150 | 0.250 |
Why?
|
| Immunomagnetic Separation | 1 | 2003 | 5 | 0.240 |
Why?
|
| Humans | 21 | 2019 | 34853 | 0.240 |
Why?
|
| Gene Expression Profiling | 3 | 2021 | 600 | 0.210 |
Why?
|
| Megakaryocytes | 1 | 2021 | 7 | 0.210 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2021 | 43 | 0.200 |
Why?
|
| Transforming Growth Factor beta | 4 | 2020 | 183 | 0.200 |
Why?
|
| Carrier Proteins | 2 | 2015 | 287 | 0.190 |
Why?
|
| Immediate-Early Proteins | 1 | 2020 | 45 | 0.180 |
Why?
|
| Female | 16 | 2021 | 19873 | 0.170 |
Why?
|
| Inflammation | 2 | 2020 | 577 | 0.170 |
Why?
|
| Leukemia, Experimental | 1 | 2018 | 4 | 0.170 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2018 | 10 | 0.170 |
Why?
|
| Muscle Fibers, Skeletal | 3 | 2008 | 60 | 0.170 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 2 | 2019 | 53 | 0.170 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2018 | 29 | 0.170 |
Why?
|
| Membrane Proteins | 3 | 2014 | 486 | 0.170 |
Why?
|
| Neoplastic Stem Cells | 1 | 2018 | 74 | 0.160 |
Why?
|
| Autoantigens | 2 | 2011 | 82 | 0.160 |
Why?
|
| Flow Cytometry | 5 | 2012 | 392 | 0.160 |
Why?
|
| Disease Models, Animal | 3 | 2016 | 1300 | 0.140 |
Why?
|
| Hypergammaglobulinemia | 1 | 2015 | 2 | 0.140 |
Why?
|
| Germinal Center | 1 | 2015 | 10 | 0.140 |
Why?
|
| Th1 Cells | 1 | 2015 | 87 | 0.140 |
Why?
|
| Interleukin-17 | 1 | 2015 | 54 | 0.130 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2014 | 91 | 0.130 |
Why?
|
| Integrin beta Chains | 1 | 2014 | 4 | 0.130 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2014 | 4 | 0.130 |
Why?
|
| Integrins | 1 | 2014 | 49 | 0.130 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2016 | 147 | 0.120 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 1 | 2013 | 4 | 0.120 |
Why?
|
| Tumor Necrosis Factors | 1 | 2013 | 12 | 0.120 |
Why?
|
| Calcium Channels | 2 | 2011 | 72 | 0.120 |
Why?
|
| Cell Culture Techniques | 2 | 2012 | 136 | 0.120 |
Why?
|
| Male | 8 | 2021 | 18870 | 0.120 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 195 | 0.120 |
Why?
|
| Lymphocytes | 2 | 2021 | 116 | 0.110 |
Why?
|
| Cell Movement | 2 | 2014 | 545 | 0.110 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2012 | 52 | 0.110 |
Why?
|
| Smad7 Protein | 1 | 2011 | 4 | 0.110 |
Why?
|
| Muscle Proteins | 2 | 2008 | 48 | 0.100 |
Why?
|
| Excitation Contraction Coupling | 1 | 2011 | 1 | 0.100 |
Why?
|
| Thiadiazoles | 1 | 2011 | 4 | 0.100 |
Why?
|
| Pyrones | 1 | 2011 | 7 | 0.100 |
Why?
|
| Muscular Atrophy | 1 | 2011 | 12 | 0.100 |
Why?
|
| Nifedipine | 1 | 2011 | 12 | 0.100 |
Why?
|
| Ovarian Neoplasms | 2 | 2006 | 303 | 0.100 |
Why?
|
| Anilides | 1 | 2011 | 27 | 0.100 |
Why?
|
| Cysteine Endopeptidases | 1 | 2011 | 57 | 0.100 |
Why?
|
| Nickel | 1 | 2011 | 19 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2011 | 25 | 0.100 |
Why?
|
| Cytokines | 2 | 2006 | 569 | 0.100 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2011 | 30 | 0.100 |
Why?
|
| Caffeine | 1 | 2011 | 26 | 0.100 |
Why?
|
| Naphthalenes | 1 | 2011 | 37 | 0.100 |
Why?
|
| Calcium Channel Blockers | 1 | 2011 | 56 | 0.100 |
Why?
|
| Electric Stimulation | 1 | 2011 | 177 | 0.100 |
Why?
|
| Cell Communication | 2 | 2008 | 93 | 0.090 |
Why?
|
| RNA, Messenger | 3 | 2020 | 1152 | 0.090 |
Why?
|
| Brucella abortus | 1 | 2009 | 5 | 0.090 |
Why?
|
| Brucellosis | 1 | 2009 | 8 | 0.090 |
Why?
|
| Cell Separation | 1 | 2010 | 91 | 0.090 |
Why?
|
| Gene Expression Regulation | 2 | 2021 | 968 | 0.090 |
Why?
|
| Spleen | 1 | 2010 | 192 | 0.090 |
Why?
|
| Cell Lineage | 1 | 2010 | 88 | 0.090 |
Why?
|
| Sarcolemma | 1 | 2008 | 3 | 0.090 |
Why?
|
| Regeneration | 1 | 2008 | 20 | 0.090 |
Why?
|
| Transport Vesicles | 1 | 2008 | 20 | 0.080 |
Why?
|
| Interleukin-10 | 2 | 2007 | 69 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2006 | 121 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 605 | 0.080 |
Why?
|
| Clonal Anergy | 2 | 2007 | 5 | 0.080 |
Why?
|
| Receptors, IgE | 1 | 2008 | 22 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2008 | 242 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 157 | 0.080 |
Why?
|
| Coronary Artery Bypass | 1 | 2008 | 43 | 0.080 |
Why?
|
| Receptor, erbB-2 | 1 | 2008 | 122 | 0.080 |
Why?
|
| Wiskott-Aldrich Syndrome Protein | 1 | 2007 | 2 | 0.080 |
Why?
|
| Wiskott-Aldrich Syndrome | 1 | 2007 | 4 | 0.080 |
Why?
|
| Mast Cells | 1 | 2008 | 77 | 0.080 |
Why?
|
| Models, Immunological | 2 | 2004 | 20 | 0.080 |
Why?
|
| Immunity, Mucosal | 1 | 2007 | 45 | 0.080 |
Why?
|
| Coronary Disease | 1 | 2008 | 113 | 0.070 |
Why?
|
| Cell Division | 2 | 2006 | 296 | 0.070 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2006 | 33 | 0.070 |
Why?
|
| Antigens, Bacterial | 1 | 2007 | 129 | 0.070 |
Why?
|
| Intestinal Mucosa | 1 | 2007 | 115 | 0.070 |
Why?
|
| Sarcoplasmic Reticulum | 1 | 2006 | 6 | 0.070 |
Why?
|
| Cloning, Molecular | 2 | 2006 | 310 | 0.070 |
Why?
|
| Transgenes | 1 | 2006 | 57 | 0.070 |
Why?
|
| Homeostasis | 1 | 2007 | 172 | 0.070 |
Why?
|
| Immune System | 1 | 2006 | 40 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2006 | 203 | 0.060 |
Why?
|
| Immunologic Techniques | 1 | 2004 | 10 | 0.060 |
Why?
|
| Antigens, Surface | 1 | 2004 | 39 | 0.060 |
Why?
|
| Antigen-Presenting Cells | 1 | 2004 | 30 | 0.060 |
Why?
|
| Epitopes | 1 | 2004 | 145 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2003 | 12 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2003 | 9 | 0.060 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2003 | 19 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2004 | 116 | 0.060 |
Why?
|
| Healthcare Disparities | 1 | 2008 | 446 | 0.060 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2002 | 67 | 0.060 |
Why?
|
| Gene Library | 1 | 2002 | 55 | 0.060 |
Why?
|
| Ovary | 1 | 2003 | 101 | 0.060 |
Why?
|
| Carcinoma | 1 | 2003 | 94 | 0.060 |
Why?
|
| Models, Biological | 1 | 2006 | 642 | 0.050 |
Why?
|
| Cell Line, Tumor | 3 | 2019 | 2128 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2011 | 1442 | 0.050 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2020 | 6 | 0.050 |
Why?
|
| Sodium Chloride | 1 | 2020 | 52 | 0.050 |
Why?
|
| Intestines | 1 | 2020 | 63 | 0.050 |
Why?
|
| Cell Line | 3 | 2008 | 1289 | 0.050 |
Why?
|
| Cell Polarity | 1 | 2020 | 53 | 0.050 |
Why?
|
| Protein Biosynthesis | 1 | 2020 | 123 | 0.040 |
Why?
|
| Hematopoiesis | 1 | 2018 | 30 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2008 | 1426 | 0.040 |
Why?
|
| Chromatin | 1 | 2018 | 164 | 0.040 |
Why?
|
| Kidney | 1 | 2020 | 322 | 0.040 |
Why?
|
| Oxidative Stress | 2 | 2016 | 874 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2012 | 430 | 0.040 |
Why?
|
| Linoleic Acid | 1 | 2016 | 7 | 0.040 |
Why?
|
| Genes, myc | 1 | 2016 | 28 | 0.040 |
Why?
|
| Methionine | 1 | 2016 | 28 | 0.040 |
Why?
|
| Hepatocytes | 1 | 2016 | 74 | 0.030 |
Why?
|
| Choline | 1 | 2016 | 57 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2016 | 109 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 2015 | 75 | 0.030 |
Why?
|
| Animals, Newborn | 2 | 2008 | 323 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 2 | 2008 | 282 | 0.030 |
Why?
|
| Colitis | 1 | 2014 | 64 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 1 | 2014 | 200 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 416 | 0.030 |
Why?
|
| Liver | 1 | 2016 | 447 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2015 | 283 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1056 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2006 | 859 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2013 | 128 | 0.030 |
Why?
|
| Mitochondria | 1 | 2016 | 454 | 0.030 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2011 | 20 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2011 | 46 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2011 | 54 | 0.030 |
Why?
|
| Lymphopenia | 1 | 2011 | 15 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2011 | 67 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 93 | 0.030 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2011 | 55 | 0.020 |
Why?
|
| Hela Cells | 1 | 2011 | 344 | 0.020 |
Why?
|
| Skin | 1 | 2011 | 173 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2011 | 162 | 0.020 |
Why?
|
| Diet | 1 | 2016 | 747 | 0.020 |
Why?
|
| Adult | 3 | 2012 | 11034 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2011 | 484 | 0.020 |
Why?
|
| Pregnancy Proteins | 1 | 2008 | 6 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2008 | 8 | 0.020 |
Why?
|
| Membrane Fusion | 1 | 2008 | 9 | 0.020 |
Why?
|
| Phosphotyrosine | 1 | 2008 | 24 | 0.020 |
Why?
|
| Extracellular Fluid | 1 | 2008 | 13 | 0.020 |
Why?
|
| Synaptophysin | 1 | 2008 | 6 | 0.020 |
Why?
|
| Pericytes | 1 | 2008 | 21 | 0.020 |
Why?
|
| Protein Binding | 1 | 2011 | 913 | 0.020 |
Why?
|
| Aged | 2 | 2012 | 6448 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2011 | 550 | 0.020 |
Why?
|
| Utilization Review | 1 | 2008 | 14 | 0.020 |
Why?
|
| Manganese | 1 | 2008 | 59 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 122 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2008 | 323 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2008 | 210 | 0.020 |
Why?
|
| Protein Transport | 1 | 2008 | 286 | 0.020 |
Why?
|
| Ligands | 1 | 2008 | 317 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2007 | 48 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2008 | 197 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2006 | 24 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2006 | 49 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2009 | 469 | 0.020 |
Why?
|
| Middle Aged | 2 | 2012 | 9642 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 2333 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2008 | 296 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2006 | 143 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 901 | 0.020 |
Why?
|
| Logistic Models | 1 | 2008 | 894 | 0.020 |
Why?
|
| Cell Death | 1 | 2006 | 260 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2007 | 490 | 0.020 |
Why?
|
| Kinetics | 1 | 2006 | 650 | 0.020 |
Why?
|
| Epithelium | 1 | 2003 | 74 | 0.010 |
Why?
|
| Methicillin Resistance | 1 | 2002 | 12 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2007 | 1318 | 0.010 |
Why?
|
| Benzamides | 1 | 2003 | 76 | 0.010 |
Why?
|
| Smad3 Protein | 1 | 2002 | 12 | 0.010 |
Why?
|
| Piperazines | 1 | 2003 | 109 | 0.010 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2002 | 24 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2003 | 112 | 0.010 |
Why?
|
| Genes, Bacterial | 1 | 2002 | 88 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 175 | 0.010 |
Why?
|
| Neutralization Tests | 1 | 2002 | 53 | 0.010 |
Why?
|
| Staphylococcus aureus | 1 | 2002 | 80 | 0.010 |
Why?
|
| Young Adult | 1 | 2012 | 4012 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2002 | 167 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 396 | 0.010 |
Why?
|
| Risk Factors | 1 | 2008 | 3414 | 0.010 |
Why?
|
| United States | 1 | 2008 | 3894 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2003 | 756 | 0.010 |
Why?
|